SecBot SecBot
8-K ·Filed Apr 10, 2026

PHGE

BiomX Inc.
BULLISH
Impact 7/10
Horizonweeks Processed7mo ago SEC0001213900-26-042200
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▲ Bullish

The acquisition immediately expands BiomX into the defense AI sector with a revenue-generating asset. Traders should monitor the future earnout payment as a key performance indicator and watch for the upcoming registration statement filing within 45 days. The significant insider selling in the past 30 days ($13.3M) suggests caution despite the bullish transaction.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.89
T+0 close · Apr 10, 2026 · via day close
Latest settled
−89.58%
T+60 · $0.3010
Vs SPY
−99.91%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 10 $2.89entry
  2. T+1 · 7mo ago −9.00%α −9.97% · $2.63
  3. T+5 · 7mo ago −36.33%α −40.84% · $1.84
  4. T+20 · 6mo ago −78.58%α −87.11% · $0.6190
  5. T+60 · 4mo ago −89.58%α −99.91% · $0.3010
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BiomX Inc. completed the acquisition of ZorroNet, an AI-powered defense technology company, using a combination of stock and a short-term promissory note. The deal expands BiomX into the defense and security sector with revenue-generating, deployed technology. The transaction includes a performance-based earnout and key employee retention provisions.

Key Financial Metrics

Deal Value
$1.3M
Deal Type
acquisition

Key Facts

  • BiomX acquired 100% of ZorroNet from Water IO Ltd.
  • Total consideration: 1,300,000 shares of PHGE stock and a $1.25M non-convertible promissory note due in 3 months.
  • Assumed obligations include a performance-based earnout payable by March 31, 2027, equal to the greater of 125% of ZorroNet's 2026 revenue or 8x EBITDA.
  • ZorroNet is a revenue-generating company with technology deployed at Israel Defense Forces bases and critical infrastructure.
  • BiomX will file a registration statement within 45 days to cover resale of the issued shares.

Financial Impact

The acquisition is valued at approximately $1.25M in cash plus stock. The future earnout is performance-based with a minimum value of 125% of 2026 revenue or 8x EBITDA.

dilutiondebtrevenueearnings

Risk Factors

  • The $1.25M note is due in 3 months and could strain liquidity if not refinanced.
  • The earnout payment is contingent on ZorroNet's 2026 financial performance.
  • Recent insider selling ($13.3M in 30 days) may indicate lack of confidence.
  • Integration risk of a new defense technology business into a biological products company.

Market Snapshot

Exchange
NYSE
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-042200
Document: ea0285346-8k_biomx.htm0001213900-26-042200
Document: ea028534601ex99-1.htm0001213900-26-042200
Document: ea028534601ex4-1.htm0001213900-26-042200
Document: 0001213900-26-042200-index-headers.html0001213900-26-042200
Document: 0001213900-26-042200-index.html0001213900-26-042200
Document: 0001213900-26-042200.txt0001213900-26-042200

US Market Status

Market Closed · Opens in 4h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 10, 2026